Search

Recursion Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

3.24 -7.16

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.22

Max

3.49

Galvenie mērījumi

By Trading Economics

Ienākumi

-14M

-131M

Pārdošana

1.2M

7.7M

EPS

-0.25

Peļņas marža

-1,708.018

Darbinieki

600

EBITDA

-10M

-113M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+83.71% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-20M

1.7B

Iepriekšējā atvēršanas cena

10.4

Iepriekšējā slēgšanas cena

3.24

Recursion Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. aug. 20:02 UTC

News
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower amid broader market declines, with analysts rating the stock as a "Hold" and price targets between $5.30 and $10.00.

2026. g. 21. aug. 20:06 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, reflecting strong momentum since Thursday's close amid favorable conditions in the biotechnology sector.

2026. g. 20. aug. 20:06 UTC

Social Media
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today, reflecting broader market trends. The stock's decline aligns with weakness in correlated assets.

2026. g. 19. aug. 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours after a volatile session, declining from the upper end of its one-month range.

2026. g. 18. aug. 20:04 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today amid broader market pressures on small-cap stocks and rising U.S. Treasury yields affecting sentiment.

2026. g. 17. aug. 19:36 UTC

Correlated Moves
News

Recursion Pharmaceuticals shares decline as Morgan Stanley cuts the price target to $5.30 from $5.50, reflecting ongoing valuation concerns.

2026. g. 12. aug. 19:56 UTC

Recursion Pharmaceuticals Inc is trading lower, reflecting a decline from Tuesday's close. The stock remains above its 20-day moving average despite today's pullback.

2026. g. 11. aug. 19:36 UTC

News

Recursion Pharmaceuticals Inc. is higher today amid positive market sentiment and over $500 million in milestone payments from partnerships with Genentech/Roche and Sanofi.

2026. g. 10. aug. 20:06 UTC

Social Media

Recursion Pharmaceuticals Inc is higher Monday amid ongoing interest, despite social media concerns about its clinical pipeline and integration challenges with Exscientia.

2026. g. 7. aug. 23:26 UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

2026. g. 6. aug. 23:26 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

2026. g. 5. aug. 23:41 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

2026. g. 4. aug. 23:31 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

2026. g. 3. aug. 20:03 UTC

Correlated Moves
News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

2026. g. 31. jūl. 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

2026. g. 30. jūl. 23:26 UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

2026. g. 29. jūl. 22:51 UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

2026. g. 28. jūl. 23:11 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares declined in after-market hours, influenced by a broader market downturn and declines in tech stocks amid AI investment concerns.

2026. g. 27. jūl. 23:46 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market trends despite gains in the DAX 30 Index amid mixed results across indices.

2026. g. 24. jūl. 23:11 UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

2026. g. 23. jūl. 19:16 UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

2026. g. 22. jūl. 23:36 UTC

Recursion Pharmaceuticals Inc. shares are near unchanged in after-market hours. The stock remains below its 20-day moving average amid rising crude oil prices.

2026. g. 21. jūl. 23:51 UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

2026. g. 20. jūl. 19:46 UTC

Correlated Moves

Recursion Pharmaceuticals is declining, continuing a trend from previous sessions, amid broader declines in the ARK Genomic Revolution ETF and Russell 2000 Index.

Salīdzinājums

Cenas izmaiņa

Recursion Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

83.71% augšup

Prognoze 12 mēnešiem

Vidējais 6.43 USD  83.71%

Augstākais 8 USD

Zemākais 5.3 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Recursion Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

1

Pirkt

3

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat